AU2017205688C1 - Cnp prodrugs with carrier attachment at the ring moiety - Google Patents

Cnp prodrugs with carrier attachment at the ring moiety Download PDF

Info

Publication number
AU2017205688C1
AU2017205688C1 AU2017205688A AU2017205688A AU2017205688C1 AU 2017205688 C1 AU2017205688 C1 AU 2017205688C1 AU 2017205688 A AU2017205688 A AU 2017205688A AU 2017205688 A AU2017205688 A AU 2017205688A AU 2017205688 C1 AU2017205688 C1 AU 2017205688C1
Authority
AU
Australia
Prior art keywords
formula
cnp
moiety
seq
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017205688A
Other languages
English (en)
Other versions
AU2017205688B2 (en
AU2017205688A1 (en
Inventor
Felix Cleemann
Ulrich Hersel
Caroline Elisabeth RASMUSSEN
Harald Rau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ascendis Pharma Endocrinology Division AS
Original Assignee
Ascendis Pharma Growth Disorders AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ascendis Pharma Growth Disorders AS filed Critical Ascendis Pharma Growth Disorders AS
Publication of AU2017205688A1 publication Critical patent/AU2017205688A1/en
Application granted granted Critical
Publication of AU2017205688B2 publication Critical patent/AU2017205688B2/en
Priority to AU2021277638A priority Critical patent/AU2021277638C1/en
Publication of AU2017205688C1 publication Critical patent/AU2017205688C1/en
Priority to AU2023210599A priority patent/AU2023210599B2/en
Priority to AU2024278289A priority patent/AU2024278289A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2017205688A 2016-01-08 2017-01-05 Cnp prodrugs with carrier attachment at the ring moiety Active AU2017205688C1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2021277638A AU2021277638C1 (en) 2016-01-08 2021-11-30 Cnp prodrugs with carrier attachment at the ring moiety
AU2023210599A AU2023210599B2 (en) 2016-01-08 2023-08-02 Cnp prodrugs with carrier attachment at the ring moiety
AU2024278289A AU2024278289A1 (en) 2016-01-08 2024-12-11 Cnp prodrugs with carrier attachment at the ring moiety

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP16150625 2016-01-08
EP16150625.8 2016-01-08
EP16179288.2 2016-07-13
EP16179288 2016-07-13
EP16191460.1 2016-09-29
EP16191460 2016-09-29
PCT/EP2017/050209 WO2017118698A1 (en) 2016-01-08 2017-01-05 Cnp prodrugs with carrier attachment at the ring moiety

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021277638A Division AU2021277638C1 (en) 2016-01-08 2021-11-30 Cnp prodrugs with carrier attachment at the ring moiety

Publications (3)

Publication Number Publication Date
AU2017205688A1 AU2017205688A1 (en) 2018-06-07
AU2017205688B2 AU2017205688B2 (en) 2021-11-04
AU2017205688C1 true AU2017205688C1 (en) 2022-03-10

Family

ID=57821955

Family Applications (4)

Application Number Title Priority Date Filing Date
AU2017205688A Active AU2017205688C1 (en) 2016-01-08 2017-01-05 Cnp prodrugs with carrier attachment at the ring moiety
AU2021277638A Active AU2021277638C1 (en) 2016-01-08 2021-11-30 Cnp prodrugs with carrier attachment at the ring moiety
AU2023210599A Active AU2023210599B2 (en) 2016-01-08 2023-08-02 Cnp prodrugs with carrier attachment at the ring moiety
AU2024278289A Pending AU2024278289A1 (en) 2016-01-08 2024-12-11 Cnp prodrugs with carrier attachment at the ring moiety

Family Applications After (3)

Application Number Title Priority Date Filing Date
AU2021277638A Active AU2021277638C1 (en) 2016-01-08 2021-11-30 Cnp prodrugs with carrier attachment at the ring moiety
AU2023210599A Active AU2023210599B2 (en) 2016-01-08 2023-08-02 Cnp prodrugs with carrier attachment at the ring moiety
AU2024278289A Pending AU2024278289A1 (en) 2016-01-08 2024-12-11 Cnp prodrugs with carrier attachment at the ring moiety

Country Status (16)

Country Link
US (3) US11413351B2 (https=)
EP (2) EP4162955A1 (https=)
JP (2) JP6968802B2 (https=)
AU (4) AU2017205688C1 (https=)
CA (1) CA3007979C (https=)
DK (1) DK3400019T3 (https=)
ES (1) ES2934582T3 (https=)
HR (1) HRP20221339T1 (https=)
HU (1) HUE060521T2 (https=)
LT (1) LT3400019T (https=)
PL (1) PL3400019T3 (https=)
RS (1) RS63793B1 (https=)
SI (1) SI3400019T1 (https=)
SM (1) SMT202200466T1 (https=)
WO (1) WO2017118698A1 (https=)
ZA (1) ZA201804415B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017118700A1 (en) 2016-01-08 2017-07-13 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with increased nep stability
IL259827B2 (en) 2016-01-08 2025-07-01 Ascendis Pharma Growth Disorders As Controlled-release CNP agonists with low initial NPR-B activity
ES3064816T3 (en) 2016-01-08 2026-04-29 Ascendis Pharma Growth Disorders As Controlled-release cnp agonists with reduced side-effects
DK3400019T3 (da) 2016-01-08 2022-10-24 Ascendis Pharma Growth Disorders As CNP-prodrugs med bærerbinding ved ringenheden
EP3400021A1 (en) * 2016-01-08 2018-11-14 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with low npr-c binding
CA3007976C (en) 2016-01-08 2023-09-26 Ascendis Pharma Growth Disorders A/S Cnp prodrugs with large carrier moieties
US11564974B2 (en) 2016-09-29 2023-01-31 Ascendis Pharma Growth Disorders A/S Combination therapy with controlled-release CNP agonists
KR20190125310A (ko) 2017-03-10 2019-11-06 퀴아펙 파마슈티칼스 에이비 방출가능한 접합체
CA3112473A1 (en) 2018-09-12 2020-03-19 Quiapeg Pharmaceuticals Ab Releasable glp-1 conjugates
MX2021008708A (es) 2019-02-11 2021-09-21 Ascendis Pharma Growth Disorders As Formulaciones farmaceuticas secas de conjugados de peptido natriuretico tipo c (cnp).
US20230192799A1 (en) * 2019-09-16 2023-06-22 Biomarin Pharmaceutical Inc. CNP Variants and Conjugates Thereof
WO2022115563A1 (en) * 2020-11-25 2022-06-02 Prolynx Llc Extended release hydrogel conjugates of c-natriuretic peptides
EP4529454A1 (en) 2022-05-23 2025-04-02 Ascendis Pharma Growth Disorders A/S Liquid pharmaceutical formulations of cnp compounds
WO2024094747A1 (en) 2022-11-02 2024-05-10 Novo Nordisk A/S Cnp compounds

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004047871A2 (en) * 2002-11-26 2004-06-10 Nobex Corporation Modified naturetic compounds, conjugates, and uses thereof
WO2010135541A2 (en) * 2009-05-20 2010-11-25 Biomarin Pharmaceutical Inc. Variants of c-type natriuretic peptide
WO2016110577A1 (en) * 2015-01-09 2016-07-14 Ascendis Pharma A/S Cnp prodrugs

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2434840T3 (es) 1995-07-27 2013-12-17 Genentech, Inc. Formulación de proteína liofilizada isotónica estable
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
WO2000018422A1 (fr) 1998-09-28 2000-04-06 Santen Pharmaceutical Co., Ltd. Promoteurs de secretion lacrymale ou gouttes ophtalmologiques contenant des peptides natriuretiques comme principes actifs pour traiter la keratoconjonctivite
PE20010212A1 (es) 1999-06-01 2001-02-22 Neuralab Ltd Composiciones del peptido a-beta y procesos para producir las mismas
BRPI0203172B8 (pt) 2001-09-28 2021-05-25 Nakao Kazuwa composição farmacêutica para acondroplasia
ES2411007T3 (es) 2001-10-10 2013-07-04 Novo Nordisk A/S Remodelación y glicoconjugación de péptidos
US7122189B2 (en) 2002-08-13 2006-10-17 Enzon, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
US7332164B2 (en) 2003-03-21 2008-02-19 Enzon Pharmaceuticals, Inc. Heterobifunctional polymeric bioconjugates
PL1620118T3 (pl) 2003-04-08 2014-11-28 Yeda Res & Dev Leki odwracalnie pegylowane
CA2763817C (en) 2003-04-08 2014-05-27 Yeda Research And Development Co. Ltd. Reversible pegylated drugs
CA2940803A1 (en) 2004-03-23 2005-10-27 Ascendis Pharma Gmbh Prodrug linker
GB2427360A (en) 2005-06-22 2006-12-27 Complex Biosystems Gmbh Aliphatic prodrug linker
CU23556A1 (es) 2005-11-30 2010-07-20 Ct Ingenieria Genetica Biotech Estructura polimérica semejante a dendrímero para la obtención de conjugados de interés farmacéutico
US8450269B2 (en) 2006-02-03 2013-05-28 Prolor Biotech Ltd. Long-acting growth hormone and methods of producing same
US9283260B2 (en) 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
US8283318B2 (en) 2006-09-08 2012-10-09 Mayo Foundation For Medical Education And Research Aquaretic and natriuretic polypeptides lacking vasodilatory activity
MX2009002859A (es) 2006-09-15 2009-03-30 Enzon Pharmaceuticals Inc Enlazadores biodegradables a base de ester impedido para suministro de oligonucleotidos.
WO2008067127A2 (en) 2006-11-09 2008-06-05 Alcon Research, Ltd. Water insoluble polymer matrix for drug delivery
CA2681567C (en) 2007-03-22 2016-07-19 The Regents Of The University Of Colorado, A Body Corporate Method of preparing an immunologically-active adjuvant-bound dried vaccine composition
KR20080098216A (ko) 2007-05-04 2008-11-07 한미약품 주식회사 캐리어 물질을 이용한 나트륨 배설 펩타이드 약물 결합체
SI2173890T1 (sl) 2007-06-21 2011-06-30 Univ Muenchen Tech Biološko aktivni proteini, ki imajo povečano in vivo in/ali in vitro stabilnost
JP2010533202A (ja) 2007-07-11 2010-10-21 エンゾン ファーマシューティカルズ，インコーポレーテッド 多置換芳香族部分を含むポリマー性薬剤送達システム
EP2217620A2 (en) 2007-11-21 2010-08-18 BioMarin Pharmaceutical Inc. Variants of c-type natriuretic peptide
BRPI0821591A2 (pt) 2007-12-21 2016-05-03 Inspiration Biopharmaceuticals Inc composição liofilizada e métodos de preparação de composição seca estável do fator ix e de liofilização de formulação farmacêutica
AU2009209565B2 (en) 2008-02-01 2013-09-19 Ascendis Pharma As Prodrug comprising a self-cleavable linker
WO2009143412A2 (en) 2008-05-23 2009-11-26 Enzon Pharmaceuticals, Inc. Polymeric systems containing intracellular releasable disulfide linker for the delivery of oligonucleotides
KR101350251B1 (ko) 2008-05-23 2014-01-14 다이이찌 산쿄 가부시키가이샤 목적 펩타이드의 혈장내 반감기 연장 작용을 가진 펩타이드
WO2009156481A1 (en) 2008-06-25 2009-12-30 Ascendis Pharma As Pegylated bnp
EP2334335A1 (en) * 2008-09-19 2011-06-22 Nektar Therapeutics Polymer conjugates of cd-np peptides
ES2610356T3 (es) 2009-02-03 2017-04-27 Amunix Operating Inc. Polipéptidos recombinantes extendidos y composiciones que comprenden los mismos
WO2011012722A1 (en) 2009-07-31 2011-02-03 Ascendis Pharma As Prodrugs containing an aromatic amine connected by an amido bond to a linker
WO2011031441A1 (en) 2009-08-28 2011-03-17 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Therapy with a chimeric molecule and a pro-apoptotic agent
MX337432B (es) 2009-12-15 2016-03-04 Ascendis Pharma As Composicion de la hormona del crecimiento seca enlazada transitoriamente a un portador del polimero.
WO2011075471A2 (en) 2009-12-18 2011-06-23 Alcon Research, Ltd. Novel npr-b agonists and methods of use for the treatment of c-type natriuretic peptide-mediated disorders
EP2519228A4 (en) 2009-12-31 2013-06-19 Enzon Pharmaceuticals Inc POLYMER CONJUGATES FROM AN AROMATIC AMINE WITH COMPOUNDS WITH A CLEANER UREA CONTAINER
US9561285B2 (en) 2010-01-22 2017-02-07 Ascendis Pharma As Carrier-linked carbamate prodrug linkers
WO2011089215A1 (en) 2010-01-22 2011-07-28 Ascendis Pharma As Dipeptide-based prodrug linkers for aromatic amine-containing drugs
US9062094B2 (en) 2010-01-22 2015-06-23 Ascendis Pharma As Dipeptide-based prodrug linkers for aliphatic amine-containing drugs
ES2993140T3 (en) 2010-04-02 2024-12-23 Amunix Pharmaceuticals Inc Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
ES2584381T3 (es) 2010-05-05 2016-09-27 Prolynx Llc Liberación controlada de compuestos activos desde conjugados macromoleculares
EP2566334B1 (en) 2010-05-05 2018-04-18 Prolynx, LLC Controlled drug release from solid supports
US9221882B2 (en) 2010-05-21 2015-12-29 Technische Universitat Munchen Biosynthetic proline/alanine random coil polypeptides and their uses
AU2012296951B2 (en) 2011-08-12 2016-09-15 Ascendis Pharma A/S Protein carrier-linked prodrugs
CA2843875C (en) 2011-08-12 2020-01-07 Ascendis Pharma A/S High-loading water-soluble carrier-linked prodrugs
CA2843506C (en) 2011-08-12 2020-05-12 Ascendis Pharma A/S Carrier-linked prodrugs having reversible carboxylic ester linkages
MX349950B (es) 2011-08-12 2017-08-22 Ascendis Pharma As Profarmacos de treprostinil enlazados a un portador.
EP2741778A1 (en) 2011-08-12 2014-06-18 Ascendis Pharma A/S Polymeric hyperbranched carrier-linked prodrugs
WO2013036857A1 (en) * 2011-09-07 2013-03-14 Prolynx Llc Sulfone linkers
EP2853273A4 (en) 2012-04-25 2016-01-13 Daiichi Sankyo Co Ltd PROMOTER FOR BONE REPAIR
CA2868925C (en) 2012-04-25 2020-01-21 Ascendis Pharma A/S Prodrugs of hydroxyl-comprising drugs
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
JP6536871B2 (ja) 2013-12-02 2019-07-03 国立大学法人京都大学 Ｆｇｆｒ３病の予防および治療剤ならびにそのスクリーニング方法
KR20160118264A (ko) 2014-02-27 2016-10-11 다이이찌 산쿄 가부시키가이샤 스테로이드제 투여로 유발되는 성장 장해에 대한 의약
CN106456695B (zh) 2014-04-28 2019-11-12 卫材R&D管理有限公司 Hgf的冻干配制品
US11633487B2 (en) 2014-08-06 2023-04-25 Ascendis Pharma A/S Prodrugs comprising an aminoalkyl glycine linker
DK3328416T5 (da) 2015-07-30 2024-10-07 Biomarin Pharm Inc Anvendelse af natriuretske peptidvarianter af c-typen til behandling af skeletdysplasi
HUE057083T2 (hu) 2015-12-08 2022-04-28 Biomarin Pharm Inc C-típusú nátriuretikus peptid változatainak alkalmazása oszteoartritisz kezelésére
ES3064816T3 (en) 2016-01-08 2026-04-29 Ascendis Pharma Growth Disorders As Controlled-release cnp agonists with reduced side-effects
WO2017118700A1 (en) 2016-01-08 2017-07-13 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with increased nep stability
EP3400021A1 (en) 2016-01-08 2018-11-14 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with low npr-c binding
CA3007976C (en) 2016-01-08 2023-09-26 Ascendis Pharma Growth Disorders A/S Cnp prodrugs with large carrier moieties
DK3400019T3 (da) 2016-01-08 2022-10-24 Ascendis Pharma Growth Disorders As CNP-prodrugs med bærerbinding ved ringenheden
IL259827B2 (en) 2016-01-08 2025-07-01 Ascendis Pharma Growth Disorders As Controlled-release CNP agonists with low initial NPR-B activity
US11564974B2 (en) 2016-09-29 2023-01-31 Ascendis Pharma Growth Disorders A/S Combination therapy with controlled-release CNP agonists
MX2021001762A (es) 2018-08-16 2021-04-19 Beyondspring Pharmaceuticals Inc Metodo y composicion para estimular la respuesta inmunitaria.
MX2021008708A (es) 2019-02-11 2021-09-21 Ascendis Pharma Growth Disorders As Formulaciones farmaceuticas secas de conjugados de peptido natriuretico tipo c (cnp).

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004047871A2 (en) * 2002-11-26 2004-06-10 Nobex Corporation Modified naturetic compounds, conjugates, and uses thereof
WO2010135541A2 (en) * 2009-05-20 2010-11-25 Biomarin Pharmaceutical Inc. Variants of c-type natriuretic peptide
US20120316114A1 (en) * 2009-05-20 2012-12-13 Biomarin Pharmaceutical Inc. Variants of C-type Natriuretic Peptide
WO2016110577A1 (en) * 2015-01-09 2016-07-14 Ascendis Pharma A/S Cnp prodrugs

Also Published As

Publication number Publication date
EP3400019A1 (en) 2018-11-14
RS63793B1 (sr) 2022-12-30
AU2021277638A1 (en) 2021-12-23
LT3400019T (lt) 2022-12-12
US20190008977A1 (en) 2019-01-10
AU2021277638B2 (en) 2023-05-18
ZA201804415B (en) 2019-03-27
DK3400019T3 (da) 2022-10-24
US11413351B2 (en) 2022-08-16
AU2024278289A1 (en) 2025-01-02
AU2023210599A1 (en) 2023-08-24
US12156917B2 (en) 2024-12-03
PL3400019T3 (pl) 2023-01-23
SI3400019T1 (sl) 2023-01-31
US20250121074A1 (en) 2025-04-17
CA3007979A1 (en) 2017-07-13
AU2023210599B2 (en) 2024-10-03
SMT202200466T1 (it) 2023-01-13
HRP20221339T1 (hr) 2023-01-06
AU2017205688B2 (en) 2021-11-04
HUE060521T2 (hu) 2023-03-28
EP3400019B1 (en) 2022-09-28
JP2022025104A (ja) 2022-02-09
CA3007979C (en) 2023-12-19
JP7816947B2 (ja) 2026-02-18
AU2017205688A1 (en) 2018-06-07
JP6968802B2 (ja) 2021-11-17
EP4162955A1 (en) 2023-04-12
JP2019510735A (ja) 2019-04-18
ES2934582T3 (es) 2023-02-23
AU2021277638C1 (en) 2023-11-09
US20220331438A1 (en) 2022-10-20
WO2017118698A1 (en) 2017-07-13

Similar Documents

Publication Publication Date Title
AU2022201416B2 (en) CNP prodrugs with large carrier moieties
AU2023210599B2 (en) Cnp prodrugs with carrier attachment at the ring moiety
AU2024200659B2 (en) Controlled-release CNP agonists with increased NEP stability
AU2022202280B2 (en) Controlled-release CNP agonists with low initial NPR-B activity
AU2017205694B2 (en) Controlled-release CNP agonists with low NPR-C binding
AU2017205273C1 (en) Controlled-release CNP agonists with reduced side-effects
HK40090963A (en) Cnp prodrugs with carrier attachment at the ring moiety

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 30 NOV 2021

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 30 NOV 2021

FGA Letters patent sealed or granted (standard patent)